Tolerance Bio is developing an allogeneic, thymus induced pluripotent stem cell (iPSC)-based cell therapy platform as well as pharmacological thymus therapies to address immune-mediated diseases caused by abnormalities in immune tolerance, including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze